Bone Therapeutics finished patient recruitment for its Phase IIA lumbar spinal fusion study.
Here are four things to know:
1. The study will test the ALLOB, the company's allogeneic bone-cell therapy product.
2. Bone Therapeutics anticipates having efficacy and safety data for the 32 patients by mid-2019.
3. The study will follow the patients for 12 months.
4. The interim results of the study revealed bone formation and pain improvement in patients with ALLOB.